The tremendous advances in the Precision Medicine field are shifting the focus of treatment towards more precise and targeted treatments that leverage intrinsic features of the immune system. As the genetic background of the patient and/or disease determines the efficacy of such therapies, there is a growing need for Companion Diagnostics (CDx) to match the right patients to the right therapy at the right time.
The co-development of a CDx between Pharma and IVD manufacturers comes with its own Grey Zones and Growing Pains, with differing regulations, submission processes, and different understanding of the roles and responsibilities. These challenges also offer opportunities to improve the ways of working and increase partnership effectiveness.
During this webinar, Kirsten van Garsse (QbD group) and Jules Petit will discuss key elements of our joint panel discussion at the 16th World Clinical Biomarkers & Companion Diagnostics Summit Europe and dive deeper into the regulatory impact of current developments and trends in the Companion Diagnostics space.
During the live webinar, we would like to answer your questions regarding the regulatory CDx Space. We invite you to submit questions during the registration for this webinar or live during our session.
Attend the webinar and receive 0.15 continuing education credits (CECs).
